Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer
NCT00862355 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2019-05-03
Summary
Bioequivalence study of SPARC147609
Conditions
- Ovarian Carcinoma
Interventions
- DRUG
-
SPARC147609
IV infusion
- DRUG
-
Reference147609
IV infusion
Sponsors & Collaborators
-
Sun Pharma Advanced Research Company Limited
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-03-31
- Primary Completion
- 2010-12-31
- Completion
- 2011-01-31
Countries
- India
More Related Trials
-
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
NCT07069335 ·Status: RECRUITING ·Phase: PHASE1
-
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
NCT04752865 ·Status: UNKNOWN
-
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
NCT01809379 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
NCT03681548 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
NCT00428610 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
NCT04091204 ·Status: UNKNOWN ·Phase: PHASE2
-
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT06437353 ·Status: RECRUITING ·Phase: PHASE2
-
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
NCT04724031 ·Status: UNKNOWN
-
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
NCT04556539 ·Status: UNKNOWN ·Phase: PHASE2
-
Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.
NCT06614790 ·Status: RECRUITING
-
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
NCT00494442 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
NCT04734665 ·Status: UNKNOWN ·Phase: PHASE2
-
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
NCT03470805 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
NCT00522301 ·Status: TERMINATED ·Phase: PHASE2
-
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
NCT03704467 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
NCT07286266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
NCT00768144 ·Status: COMPLETED ·Phase: PHASE2
-
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT06121401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
NCT02983799 ·Status: COMPLETED ·Phase: PHASE2
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
NCT00831636 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
NCT01610869 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
NCT00058552 ·Status: COMPLETED ·Phase: PHASE2